News | May 03, 2023
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
Several late-stage pipeline products have the potential to address some of these unmet needs
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
To create leading company developing medicines targeting metalloenzymes
The use of procalcitonin testing for sepsis management is highest in the US
He brings over 30 years of experience across various organizations such as Asian Paints PPG, Berger Paints, Tata Steel, among others
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Subscribe To Our Newsletter & Stay Updated
